CA
NZ
UK
AU
IND
US
…
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Fractyl Health develops an endoscopic metabolic procedure to improve glycemic control in people with type 2 diabetes and related metabolic disease. Long-term growth drivers include a large, growing diabetes population, demand for alternatives to chronic drugs, and potential adoption of minimally invasive interventions; the company may appeal to investors seeking exposure to device-based diabetes solutions.
Key risks include uncertain clinical trial outcomes, regulatory and reimbursement hurdles, competition from drugs and other devices, limited commercial history, and possible need for additional capital.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | -140.95M | -68.69M | -77.09M | -46.45M | -38.73M |
| Net income | -140.95M | -68.69M | -77.09M | -46.45M | -38.73M |
| Selling general administrative | 22.28M | 23.10M | 12.84M | 15.03M | 10.49M |
| Gross profit | -1.13M | 0.04M | 0.04M | 0.00M | - |
| Reconciled depreciation | 1.13M | 0.68M | 0.29M | 0.45M | 0.68M |
| Ebit | -96.82M | -93.53M | - | - | - |
| Ebitda | -95.69M | -92.85M | - | - | - |
| Depreciation and amortization | 1.13M | 0.68M | - | - | - |
| Operating income | -96.82M | -93.53M | -50.84M | -49.38M | -36.93M |
| Other operating expenses | 96.82M | 93.62M | - | - | - |
| Interest expense | - | - | - | - | 1.44M |
| Interest income | 1.54M | 4.15M | 1.26M | 0.80M | - |
| Net interest income | 1.54M | 4.15M | 1.26M | 0.80M | -1.44M |
| Total revenue | 0.00M | 0.09M | 0.12M | 0.00M | 0.00M |
| Total operating expenses | 95.69M | 93.57M | 50.96M | 49.38M | 36.93M |
| Cost of revenue | 1.13M | 0.05M | 0.08M | 0.00M | - |
| Total other income expense net | -44.14M | 24.84M | -27.52M | 2.13M | -0.36M |
| Net income from continuing ops | -140.95M | -68.69M | -77.09M | -46.45M | -38.73M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 121.40M | 108.08M | 76.21M | 60.96M | 102.55M |
| Intangible assets | - | 0.83M | - | - | - |
| Other current assets | 6.04M | 4.23M | 2.03M | 2.36M | 0.92M |
| Total liab | 111.94M | 79.65M | 401.27M | 313.27M | 311.87M |
| Total stockholder equity | 9.46M | 28.42M | -325.06M | -252.32M | -209.32M |
| Other current liab | 11.65M | 11.58M | 0.57M | 0.04M | 0.10M |
| Common stock | 0.00M | - | - | - | - |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -556.26M | -415.31M | -346.62M | -269.52M | -223.07M |
| Cash | 81.54M | 67.46M | 33.21M | 49.27M | 95.47M |
| Total current liabilities | 18.33M | 19.77M | 11.19M | 7.31M | 23.65M |
| Net debt | -19.89M | -4.96M | 21.94M | - | - |
| Short term debt | 5.10M | 4.96M | - | - | - |
| Short long term debt | - | - | - | - | 15.72M |
| Short long term debt total | 61.65M | 62.50M | - | - | - |
| Other stockholder equity | 565.72M | 443.73M | - | - | - |
| Total current assets | 87.58M | 71.76M | 35.65M | 51.63M | 96.39M |
| Net receivables | - | 0.02M | 0.02M | 0.00M | - |
| Long term debt | 30.59M | 30.16M | 55.15M | 17.76M | - |
| Inventory | 0.00M | 0.07M | 0.07M | 0.00M | - |
| Accounts payable | 1.57M | 3.24M | 0.55M | 0.98M | 0.97M |
| Non currrent assets other | 0.34M | 0.67M | 9.79M | 7.68M | 4.82M |
| Non current assets total | 33.83M | 36.31M | 40.56M | 9.33M | 6.16M |
| Capital lease obligations | 31.06M | 32.34M | 31.24M | 1.72M | 1.28M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | - | -1.76M | -0.36M | -0.06M | -0.05M |
| Total cashflows from investing activities | -0.56M | -1.76M | - | - | - |
| Net borrowings | -0.46M | -0.19M | - | - | - |
| Total cash from financing activities | 104.96M | 101.23M | 27.44M | 4.35M | 99.88M |
| Net income | -140.95M | -68.69M | -77.09M | -46.45M | -38.73M |
| Change in cash | 14.08M | 33.94M | -15.74M | -41.95M | 66.37M |
| Begin period cash flow | 71.72M | 37.78M | 53.52M | 95.47M | 29.11M |
| End period cash flow | 85.80M | 71.72M | 37.78M | 53.52M | 95.47M |
| Total cash from operating activities | -90.33M | -65.52M | -42.82M | -46.24M | -33.46M |
| Issuance of capital stock | 85.40M | 103.69M | - | 0.00M | 99.85M |
| Depreciation | 1.13M | 0.68M | 0.29M | 0.45M | 0.68M |
| Change to inventory | 0.07M | -0.07M | -0.07M | 0.00M | - |
| Change to account receivables | 0.00M | 0.02M | -0.02M | 0.00M | - |
| Other cashflows from financing activities | - | -2.28M | - | - | - |
| Capital expenditures | 0.56M | 1.76M | 0.36M | 0.06M | 0.05M |
| Change in working capital | -0.40M | 9.59M | 0.99M | -1.24M | 1.71M |
| Stock based compensation | 6.68M | 14.43M | 4.30M | 3.14M | 2.09M |
| Other non cash items | 43.21M | -21.52M | 21.90M | -2.31M | 0.43M |
| Free cash flow | -90.89M | -67.29M | -43.18M | -46.30M | -33.51M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| GUTS Fractyl Health, Inc. Common Stock |
0.02 3.34% |
0.49 | - | - | 7575.74 | 5.06 | 16846.11 |
| NVO Novo Nordisk A/S |
0.18 0.47% |
38.80 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
3.81 0.73% |
526.19 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
-7.98 1.00% |
788.04 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
- -% |
1010.26 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Harith Rajagopalan M.D., Ph.D. | Co-Founder, CEO & Director | 1977 |
| Mr. Jay D. Caplan BSEE, MBA | Co-Founder, Chief Product Officer & President | 1962 |
| Dr. Timothy J. Kieffer Ph.D. | Chief Scientific Officer | 1967 |
| Ms. Lisa A. Davidson MBA | CFO & Treasurer | 1967 |
| Ms. Sarah S. Toomey Esq. | General Counsel & Corporate Secretary | 1975 |
| Dr. Helmut Giersiefen | Head of Business Development | NA |
| Mr. Adrian Kimber | Chief Commercial Officer | NA |
| Ms. Lara Smith Weber | CFO & Treasurer | NA |
| Mr. Brian Luque | Head of Investor Relations & Corporate Development | NA |
| Mr. Jon Fitzgerald | Senior Vice President of Regulatory, Quality & Clinical | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.18%
Communication Services
+0.02%
Consumer Cyclical
+0.43%
Consumer Defensive
+0.03%
Energy
-0.27%
Financial Services
+0.32%
Financials
-0.23%
Healthcare
-0.17%
Industrials
+0.45%
Real Estate
-0.02%
Technology
+0.20%
Utilities
+0.20%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...